Compare Neurocrine Biosciences Inc (NBIX) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Advanced Drainage Systems Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Advanced Drainage Systems Inc trades at $131.78 (market cap $10.08B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Advanced Drainage Systems Inc pays a 0.6% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | WMS | |
|---|---|---|
Market Cap | $15.77B | $10.08B |
Sector | Health | Industrials |
52-Week High | $185.50 | $175.38 |
52-Week Low | $123.10 | $129.50 |
Enterprise Value | $15.78B | $11.68B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Advanced Drainage Systems (WMS) trades at $133.67, down 1.54% on the day, amid a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.49 exceeding the $2.10 forecast. Revenue for 2025 was $2.90 billion, with a net income margin of 15.5%. Analyst consensus is a Buy with a $188.20 price target, though technical indicators show selling pressure. Recent news highlights institutional buying and strong Q1 2027 results.
The outlook for WMS is mixed; strong fundamentals and analyst optimism contrast with near-term technical weakness. Investment opportunities include market share gains and acquisition synergies, while risks involve cyclical construction exposure and rising investing cash outflows. The stock's current price offers a potential upside to the consensus target, but investors should weigh execution risks against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
